<DOC>
	<DOCNO>NCT00775138</DOCNO>
	<brief_summary>This study determine safety tolerability 28 day daily dose two dos ( 280mg 560mg ) Arikace™ versus placebo patient Bronchiectasis .</brief_summary>
	<brief_title>A Study Determine Safety Tolerability Arikace™ Versus Placebo Patients Who Have Bronchiectasis .</brief_title>
	<detailed_description>Bronchiectasis chronic disorder major bronchus bronchiole characterize permanent dilation , microbial infection , persistent inflammatory response release immune mediator microbial toxin lead destruction . The origin bronchiectasis varies , presence microbial infection persistent inflammatory response typical disease . The chronic nature infection associate considerable morbidity provide rationale use aerosolized antibiotic treatment bronchiectasis patient . This multi-national Phase 2 study safety tolerability 28 day daily dose two dose level ( 280 mg 560 mg ) Arikace™ versus placebo subject bronchiectasis ( BR ) chronic pseudomonas infection . Study subject randomize receive either study drug placebo inhalation via PARI eFlow nebulizer . Each subject complete 28 day daily dose . All study subject follow microbiologic activity 14 day completion treatment safety 28 day post completion study treatment . The total study duration 56 day , screen visit occur within precede 14 day prior study day 1 . At Day 1 ( baseline ) , subject evaluate pre-dose first 4-5 hour post-dose . Subjects return 2 week ( day 14 ) start treatment end 4 week ( Day 28 ) treatment period determine safety , efficacy Arikace™ . Subjects follow study day 42 56 ( 2 4 week end treatment ) safety determination . After completion study , subject , follow additional 6 month via phone contact record review , hospitalize treat pulmonary exacerbation ( extension protocol ) . Clinical laboratory parameter , audiology testing , clinical adverse event pulmonary function evaluate study subject order determine qualitative quantitative safety tolerability Arikace™ compare placebo . Serum , urine sputum specimen collect periodic interval assess PK subjectswho consent PK portion study . Additionally , sputum sample collect determine change bacterial density . Total Pulmonary Symptom Severity Score assess , Respiratory quality life evaluate use St. George 's Respiratory Questionnaire ( SGRQ ) .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Male female study subjects≥ 18 year age Confirmed diagnosis multifocal bronchiectasis two lung segment HRCT chest History chronic infection P. aeruginosa Confirmation infection P. aeruginosa screen SaO2 ≥ 90 % Screening breathing room air Ability comply study medication use , study visit , study procedure judge investigator Ability produce least 0.5 gram sputum willing undergo induction produce sputum clinical evaluation Forced Expiratory Volume 1 second ( FEV1 ) &lt; 50 % predict Screening Bronchiectasis due cystic fibrosis ( CF ) , bronchopulmonary Aspergillus , aspiration foreign body , secondary lung compression tumor History nontuberculous mycobacterial and/or Aspergillus infection require treatment treat within 2 year prior screen Pulmonary tuberculosis require treatment treat within two year prior screen History Lung transplantation Use inhalation systemic antibiotic ( IV antibiotic , oral antibiotic ) within 4 week prior Study Day 1 Evidence biliary cirrhosis portal hypertension Smoking tobacco substance within 6 month prior screen , throughout study History alcohol , medication , illicit drug abuse within 1 year prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bronchiectasis</keyword>
	<keyword>Respiratory Infections</keyword>
	<keyword>Amikacin</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Respiratory Tract Infections</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Infant , Newborn , Diseases</keyword>
	<keyword>Pancreatic Diseases</keyword>
</DOC>